Stocks Struggle After OpenAI IPO Blow: Stock Market Today
Stocks took an early hit on news that ChatGPT parent OpenAI might push its public offering to 2027, and a midday recovery faded into the close.
Stocks opened lower Friday as tech stocks slumped on reports that artificial intelligence (AI) giant OpenAI is considering delaying its initial public offering (IPO). And while the main equity indexes were in positive territory by lunchtime thanks to strength in defensive sectors, including healthcare and consumer staples, momentum faded into the close.
Late Thursday, The New York Times reported that advisers to OpenAI are encouraging CEO Sam Altman to delay the ChatGPT parent's offering until 2027. This comes amid recent volatility in SpaceX (SPCX, +0.2%), which went public earlier this month in the biggest IPO ever.
OpenAI confidentially filed its IPO paperwork with the Securities and Exchange Commission in early June, with some suggesting it could go public as soon as Q3 2026.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
But a potential delay "is a rational, strategically sound decision by one of the most sophisticated management teams and advisory networks in the technology industry," says Luke Lango, lead technology and cryptocurrency analyst at InvestorPlace.
Lango believes OpenAI would be going public "in a competitive environment where Anthropic's rapid progress has created legitimate uncertainty about long-term market share dynamics" and "in a market that just watched SPCX's $1.75 trillion IPO produce more volatility than anyone wanted."
The news sent the Nasdaq Composite down more than 1% at Friday's open, though the tech-heavy index closed with a more modest loss of 0.2% to 25,297. Memory chip stocks created some of the biggest headwinds for the Nasdaq, with Micron Technology (MU, -6.7%) and Sandisk (SNDK, -10.5%) both posting notable losses on Friday.
Elsewhere, the broader S&P 500 slipped 0.05% to 7,354, while the blue-chip Dow Jones Industrial Average — which will add Google parent Alphabet (GOOGL, -2.2%) to its 30-stock roster on Monday — fell 0.09% to 51,876.
ON Semiconductor sinks 24% on deal drama
ON Semiconductor (ON) was another notable tech loser on Friday, sinking 23.7% to make it the worst S&P 500 stock of the day, after the chip manufacturer said it will buy Synaptics (SYNA, -3.7%) in an all-stock deal valued at roughly $7 billion. This also marks ON's largest single-day drop since October 2023.
"By adding Synaptics' differentiated Edge AI compute franchise and strong portfolio of human-machine interface and wireless connectivity solutions, onsemi is expected to extend its capabilities beyond power and sensing to intelligent systems, delivering greater value to a broad range of end markets," ON Semi explained in the press release.
Looking for more timely stock market news to help gauge the health of your portfolio? Sign up for Closing Bell, our free newsletter that's delivered straight to your inbox at the close of each trading day.
The reaction from market participants is likely "an investor preference for a data center rather than edge enhancement," says B. Riley Securities analyst Craig Ellis. But Ellis believes it's "a logical product line extension play from data center AI toward the edge for significant SAM expansion into a $100 billion CY30 AI opportunity now including more humanoids and robotics."
Ellis reiterated his Buy rating on ON and lifted his price target to $135 from $118.
Moderna stock soars on sector rotation, drug news
On the plus side of Friday's ledger was Moderna (MRNA), which rose 12.6% to put it at the top of the S&P 500. In addition to a broader rotation into defensive stocks, the drugmaker got a boost after unveiling its first in vivo CAR-T autoimmune therapy program during Thursday's investor day.
"We do think there is investor interest more broadly in the oncology pipeline and new sources of future growth and diversification beyond infectious disease and COVID/Flu, etc.," says UBS Global Research analyst Michael Yee.
But the new programs discussed on Thursday won't be potential growth drivers until at least 2030, Yee says. As such, focus for now is on the company's INT cancer vaccine, with Phase III data expected later this year, and lowering operational expenditures to reach breakeven.
Yee has a cautious Neutral (Hold) rating on the healthcare stock and a $45 price target — more than 30% below its current price.
Related content
- Why Invest In Mutual Funds When ETFs Exist?
- Requiem for Maestro: 5 Lessons From Fed Chair Alan Greenspan
- Stock Market Holidays in 2026: NYSE, NASDAQ and Wall Street Holidays
